• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The new therapy of loss of pregnancy ~ Endothelial progenitor cells for vascular medicine and recombinant human soluble thrombomodulin

Research Project

Project/Area Number 15K20168
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Obstetrics and gynecology
Research InstitutionOsaka Medical College

Principal Investigator

Fujita Daisuke  大阪医科大学, 医学部, 講師 (90411371)

Research Collaborator SANO Takumi  大阪医科大学, 医学部, 助教 (30817185)
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords不育症 / 遺伝子組換え型ヒトトロンボモジュリン製剤 / リコモジュリン / 抗凝固療法 / sFlt-1 / preeclampsia / 妊娠高血圧腎症 / 習慣性流産 / 抗凝固薬 / ヘパリン / アスピリン / トロンボモジュリン / 不育症治療 / 死産 / 流産 / 生児獲得 / 流産マウス / 不育症マウス
Outline of Final Research Achievements

Recombinant human Thrombomodulin(r-TM) as an anticoagulation therapy has the potential for the medical treatment of recurrent miscarriage and fetal growth restriction due to improved angiogenic factors. Additionally, r-TM treatment has the potential for the recovery of preeclampsia.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report

Research Products

(1 results)

All 2017

All Presentation (1 results)

  • [Presentation] 流産モデルマウスを用いたrecombinant thrombomodulin投与による不育症治療の可能性2017

    • Author(s)
      佐野匠
    • Organizer
      第69回日本産科婦人科学会学術講演会
    • Place of Presentation
      広島
    • Year and Date
      2017-04-13
    • Related Report
      2016 Research-status Report

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi